9 Sep 2010 15:54
| For immediate release | 9 September 2010 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Director Share Transfer
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, was notified today that on 8 September 2010 John Dawson, a Director of the Company, gifted for nil consideration 10,000,000 ordinary shares of 1p each in the Company ("Ordinary Shares") to some family trusts in which he retains a beneficial interest and 10,000,000 Ordinary Shares to a family trust in which he has a non-beneficial interest.
Following this transfer, Mr Dawson has a beneficial interest in 52,261,402 Ordinary Shares representing 22.22% of the Company's issued share capital and a non-beneficial interest in 10,000,000 Ordinary Shares representing 4.25% of the Company's issued share capital.
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 |
| John Dawson, Chief Executive Officer |
|
| Richard Wright, Finance Director |
|
| www.alliancepharma.co.uk |
|
Buchanan Communications | + 44 (0) 20 7466 5000 |
| Mark Court / Jessica Fontaine |
|
|
|
|
| Numis Securities Limited | + 44 (0) 20 7260 1000 |
| Nominated Adviser: Michael Meade / Simon Blank |
|
| Corporate Broking: David Poutney |
|
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are distributed both to hospitals directly and to pharmaceutical wholesalers, which in turn service both hospital and retail pharmacies with their prescription requirements.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
Alliance Pharma (APH)